Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide

Journal of Clinical Pharmacology

Volumn 50, Issue 8, 2010, Pages 886-894

  Watson, Estelle ^a   Jonker, Daniël M ^a   Jacobsen, Lisbeth V ^a   Ingwersen, Steen H ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Exenatide; glucagon like peptide 1; liraglutide; population pharmacokinetics; type 2 diabetes

Indexed keywords

EXENDIN 4; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CALIBRATION; CLINICAL STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION MODEL; PUBLICATION; VALIDATION STUDY; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PEPTIDES; VENOMS;

EID: 77955820667     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009354996     Document Type: Article

References (21)

1. Baggio L., Drucker D. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 ; 132: 2131-2157.
2. Zander M., Madsbad S., Madsen JL, Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002 ; 359: 824-830.
3. Vilsboll T., Agerso H., Krarup T., Holst JJ Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003 ; 88: 220-224.
4. Knudsen LB, Nielsen OPF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000 ; 43: 1664-1669.
5. Madsen K., Knudsen LB, Agersoe H., et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007 ; 50: 6126-6132.
6. Steensgaard DB, Thomsen JK, Olsen B., Knudsen LB The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes. 2008 ; 57 (suppl 1). A164.
7. Elbrønd B., Jakobsen G., Larsen S., et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002 ; 25: 1398-1404.
8. Damholt B., Golor G., Wierich W., Pedersen P., Ekblom M., Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006 ; 46: 635-641.
9. Agersø H., Jensen LB, Elbrønd B., Rolan P., Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002 ; 45: 195-202.
10. Linnebjerg H., Kothare PA, Park S., et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007 ; 64: 317-327.
11. Holst JJ Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs. 2004 ; 9: 155-166.
12. Buse J., Rosenstock J., Sesti G.,, et al. for the LEAD 6 study group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009 ; 374: 39-47.
13. Juhl CB, Hollingdal M., Sturis J., et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002 ; 51: 424-429.
14. Nauck MA, El-Quaghlidi A., Hompesch M., Jacobsen J., Elbrønd B. No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes. Diabetes. 2003 ; 52 (suppl 1). A128.
15. Vilsbøll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as mono-therapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007 ; 30: 1608-1610.
16. Calara F., Taylor K., Han J., et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005 ; 27: 210-215.
17. Larsen J., Hylleberg B., Ng K., Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care. 2001 ; 24: 1416-1421.
18. DeFronzo RA, Ratner RE, Han J., Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005 ; 28: 1092-1100.
19. Kendall DM, Riddle MC, Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005 ; 28: 1083-1091.
20. Nauck MA, Hompesch M., Filipczak R.,, et al. NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006 ; 114: 417-423.
21. Bjornsdottir I., Olsen A., Larsen U., et al. Metabolism and excretion of the once-daily human GLP-1 analogue in healthy subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase [abstract]. Diabetologia. 2008 ; 51 (suppl 1). S356.